MAPT and Alzheimer disease: In conclusion, the above results show that CS-Li possesses the ability to inhibit the aggregation of Aβ, reduce the damage of oxidative stress, regulate tau hyperphosphorylation, decrease inflammation response to decelerate AD progression, and improve learning and memory abilities of AD mice by simultaneously acting on multitargets.